Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Adele Chedraoui is active.

Publication


Featured researches published by Adele Chedraoui.


Dermatologic Therapy | 2013

Successful treatment of hydroquinone‐resistant melasma using topical methimazole

Joelle Malek; Adele Chedraoui; Damian Nikolic; Neda Barouti; Samer Ghosn; Ossama Abbas

Melasma is an acquired hyperpigmentation skin disorder in sun‐exposed areas. It occurs almost exclusively over the face, and is most commonly seen in women. Several depigmenting agents have been used for the treatment of melasma among which hydroquinone has been the most widely used due to its efficacy and safety in short‐term use. However, hydroquinone is recently reported to be a cytotoxic and mutagenic compound in mammalian cells and is thus banned in several countries. Hydroquinone ban has caused investigators to search for alternative depigmenting agents for the treatment of melasma in recent years. Methimazole is an antithyroid agent orally used in humans since several decades and has been shown that when applied topically, it inhibits melanin synthesis and causes skin depigmentation in lab animals as well as human subjects. Herein, we report two hydroquinone‐resistant melasma patients who were successfully treated with methimazole cream. Application of 5% methimazole cream once daily resulted in significant improvement of melasma in both patients after 8 weeks. The efficacy of methimazole for melasma treatment as well as its advantages over other known depigmenting compounds (non‐mutagenicity, non‐cytotoxicity and high tolerability profile) suggests that topical methimazole should be added to the armamentarium of anti‐melasma treatment.


International Journal of Dermatology | 2010

Acral pseudolymphomatous angiokeratoma of children in an elderly man: report of a case and review of the literature.

Adele Chedraoui; Joelle Malek; Hussam Tamraz; Shukrallah Zaynoun; Abdul Ghani Kibbi; Samer Ghosn

Acral pseudolymphomatous angiokeratoma of children (APACHE) is clinically characterized by angiomatous papules that preferentially affect acral areas of children. It is currently believed to be a variant of pseudolymphoma rather than angiokeratoma. Histopathologically, a mixed inflammatory cell infiltrate comprising B‐ and T‐lymphocytes and a proliferation of thick‐walled blood vessels are the hallmark. In the literature, although more adult cases are being described, the clinical, epidemiologic and histopathologic data of this presentation is scant. We report a 76‐year‐old man who presented with a 5‐year history of progressively increasing asymptomatic dusky dome‐shaped papules and plaques on his upper and lower extremities. Histology was consistent with APACHE. After reviewing all the adult cases in the literature and comparing them to the classical variant in children, we found no significant difference warranting separating these two variants. We prefer the designation “papular angiolymphoid hyperplasia” to APACHE as it encompasses all the childhood and adult cases involving acral and nonacral sites and highlights the histological and sometimes clinical similarities this entity shares with angiolymphoid hyperplasia with eosinophilia.


Journal of The American Academy of Dermatology | 2008

Localized involutional lipoatrophy with epidermal and dermal changes

Ossama Abbas; Salah Salman; Abdul Ghani Kibbi; Adele Chedraoui; Samer Ghosn

Localized involutional lipoatrophy (LIL) was first described in 1986 as a distinctive idiopathic form of localized lipoatrophy characterized by loss of adipose tissue without antecedent inflammation. Clinically, LIL usually presents as a solitary, asymptomatic, well-demarcated, atrophic depression and often involves areas of antecedent intramuscular or intra-articular injections. Histologically, changes in the subcutaneous fat in LIL resemble fetal adipose tissue. Only rarely has there been any description of epidermal or dermal changes occurring with LIL. We describe two cases of LIL with overlying hypopigmentation and atrophy, and with morphea-like changes on histology. Recognition of these changes may have clinical and diagnostic implications.


Journal of Dermatological Treatment | 2008

Red scrotum syndrome: Successful treatment with oral doxycycline

Ossama Abbas; Abdul Ghani Kibbi; Adele Chedraoui; Samer Ghosn

Background: Red scrotum syndrome often follows the prolonged application of topical corticosteroids to the scrotal area and is characterized by persistent erythema of the scrotum associated with severe itching, hyperalgesia, and a burning sensation. Several topical and systemic treatments have been used in the past without success. Objective: To assess the efficacy of oral doxycycline, in addition to corticosteroid abstinence, in the treatment of red scrotum syndrome. Methods: In a retrospective chart review, seven patients with red scrotum syndrome, who presented between 2004 and 2007 to the outpatient clinic at the American University of Beirut Medical Center, were identified as having been treated with oral doxycycline and steroid abstinence. Results: All patients reported significant improvement (between 50% and 80%) of their symptoms within 2 weeks of starting doxycycline and had marked improvement of the erythema and complete resolution of symptoms in a period ranging from 2 to 3 months. Conclusion: We suggest that doxycycline may be effective in the treatment of red scrotum syndrome.


American Journal of Dermatopathology | 2009

Genitogluteal porokeratosis: 10 years to make the diagnosis!

Joelle Malek; Adele Chedraoui; Abdul Ghani Kibbi; Samer Ghosn

Genitogluteal porokeratosis, a relatively rare presentation of porokeratosis of Mibelli, often manifests in an atypical way due to its verrucous appearance that may obscure the characteristic annular keratotic rim. For this reason, misdiagnosis as other common papulosquamous diseases is not uncommon. We report a 44-year-old man with a 10-year-history of slowly progressive pruritic psoriasiform/lichenified plaques over the buttocks. Despite multiple skin biopsies, the lesions were misdiagnosed as psoriasis, lichen simplex chronicus, pityriasis rubra pilaris, and mycosis fungoides, until the last biopsy revealed findings characteristic of porokeratosis. Dermatologists and dermatopathologists should be aware of this rare and unique variant of porokeratosis, which, in addition to the atypical clinical presentation and the occasional misleading histology, may portend a better prognosis in terms of malignant degeneration.


Scopus | 2013

Successful treatment of hydroquinone-resistant melasma using topical methimazole

Adele Chedraoui; Ossama Abbas; N Barouti; Samer Ghosn; D Nikolic; Joelle Malek

Melasma is an acquired hyperpigmentation skin disorder in sun‐exposed areas. It occurs almost exclusively over the face, and is most commonly seen in women. Several depigmenting agents have been used for the treatment of melasma among which hydroquinone has been the most widely used due to its efficacy and safety in short‐term use. However, hydroquinone is recently reported to be a cytotoxic and mutagenic compound in mammalian cells and is thus banned in several countries. Hydroquinone ban has caused investigators to search for alternative depigmenting agents for the treatment of melasma in recent years. Methimazole is an antithyroid agent orally used in humans since several decades and has been shown that when applied topically, it inhibits melanin synthesis and causes skin depigmentation in lab animals as well as human subjects. Herein, we report two hydroquinone‐resistant melasma patients who were successfully treated with methimazole cream. Application of 5% methimazole cream once daily resulted in significant improvement of melasma in both patients after 8 weeks. The efficacy of methimazole for melasma treatment as well as its advantages over other known depigmenting compounds (non‐mutagenicity, non‐cytotoxicity and high tolerability profile) suggests that topical methimazole should be added to the armamentarium of anti‐melasma treatment.


Acta Dermato-venereologica | 2008

Adrenergic Urticaria in a Patient with Anti-double-stranded DNA Antibodies

Adele Chedraoui; Imad Uthman; Ossama Abbas; Samer Ghosn

Adrenergic urticaria, a rare but distinct subtype of the physical urticarias, is characterized by wheals that are typically surrounded by a white halo of vasoconstriction, and by a positive response to intradermal adrenaline and noradrenaline injections. The pathogenesis of adrenergic urticaria is unknown. We report here a case of a 64-year-old woman with adrenergic urticaria who was found to have high levels of anti-double-stranded DNA antibodies without features of systemic lupus erythematosus. This is the first report associating adrenergic urticaria with anti-double-stranded DNA antibodies. The significance of this association is unknown.


JAMA Dermatology | 2018

Use of Topical Glycolic Acid Plus a Lovastatin-Cholesterol Combination Cream for the Treatment of Autosomal Recessive Congenital Ichthyoses

Samar Khalil; Tara Bardawil; Serena Saade; Adele Chedraoui; Nehmat Ramadan; Divina Justina Hasbani; Ossama Abbas; Georges Nemer; Nelly Rubeiz; Mazen Kurban

Importance Autosomal recessive congenital ichthyosis (ARCI) is a heterogeneous group of disorders caused by defects in signaling pathways involved in epidermal proliferation and differentiation, leading to a wide range of skin manifestations. Therapeutic options are limited and often unsatisfactory. Topical cholesterol and statin as a combined formulation has proven successful in the treatment of patients with CHILD syndrome (congenital hemidysplasia ichthyosis and limb defects). Objective To assess change in disease severity score after a 3-month therapeutic regimen consisting of a glycolic acid, 10% to 20%, cream and a combination cream of lovastatin, 2%, with cholesterol, 2%, in the treatment of ARCI. Design, Setting, and Participants This case series of 15 patients with ARCI was conducted at the American University of Beirut, a referral center in the Middle East region for genodermatoses, between May 2017 and January 2018. No age groups were excluded; all patients were from the Middle East area; and all were initially not responsive to treatment with hydrating creams in combination with urea creams, 30% to 40%, or glycolic acid, 10% to 20%. Excluded were patients who had been taking systemic retinoids within 3 months before the start of the study. Interventions A 3-month therapeutic regimen of glycolic acid, 10% to 20%, cream and a combination of lovastatin, 2%, with cholesterol, 2%, cream. Main Outcomes and Measures Percentage change in disease severity scores following 2 and 3 months of study treatment. Results Of the 15 patients included in the study, 10 were male (mean age, 11.2 years; age range, 2-38 years). The average percentage reduction in the disease severity score was 33.7% at 2 months (from 60.8 to 40.2) and 57.5% at 3 months (from 60.8 to 21.9). Adverse effects were mild and consisted mainly of irritation and burning. Conclusions and Relevance These findings suggest a benefit from a treatment regimen consisting of glycolic acid, 10% to 20%, and a combination of lovastatin, 2%, with cholesterol, 2%, in the treatment of ARCI. This combination of creams might also prove to be beneficial in other types of ichthyoses and other dermatological diseases with a defective skin barrier.


Clinical and Experimental Dermatology | 2010

Bilateral auricular pseudocysts as the presenting sign of hepatocellular carcinoma

Ossama Abbas; Adele Chedraoui; J. A. Baki; Abdul-Ghani Kibbi; Samer Ghosn

ENGEL D, 1966, ARCHIV OTOLARYNGOL, V83, P197; HOFFMANN TJ, 1993, J DERMATOL SURG ONC, V19, P259; Li LJ, 2001, ARCH DERMATOL, V137, P657; Ng W, 2007, J AM ACAD DERMATOL, V56, P858, DOI 10.1016-j.jaad.2007.01.038; Pereira FC, 2003, INT J DERMATOL, V42, P818, DOI 10.1046-j.1365-4362.2003.01764.x; SANTOS AD, 1995, PEDIATR DERMATOL, V12, P152, DOI 10.1111-j.1525-1470.1995.tb00143.x


Clinical and Experimental Dermatology | 2009

Multiple asymptomatic skin-coloured papules on the left great and second toes

Ossama Abbas; Adele Chedraoui; Abdul-Ghani Kibbi; M. Zayour; Samer Ghosn

Hager CM, 1997, J AM ACAD DERMATOL, V37, P864, DOI 10.1016-S0190-9622(97)80013-8; Pu LLQ, 2004, MICROSURG, V24, P67, DOI 10.1002-micr.10201; Ruggieri M, 2000, J NEUROSURG, V93, P530; Secchi T, 1996, ANN DERMATOL VENER, V123, P487; Sugiura K, 2004, INT J DERMATOL, V43, P451, DOI 10.1111-j.1365-4632.2004.02116.x; WELEBER RG, 1983, AM J OPHTHALMOL, V96, P740

Collaboration


Dive into the Adele Chedraoui's collaboration.

Top Co-Authors

Avatar

Samer Ghosn

American University of Beirut

View shared research outputs
Top Co-Authors

Avatar

Ossama Abbas

American University of Beirut

View shared research outputs
Top Co-Authors

Avatar

Abdul Ghani Kibbi

American University of Beirut

View shared research outputs
Top Co-Authors

Avatar

Joelle Malek

American University of Beirut

View shared research outputs
Top Co-Authors

Avatar

Abdul-Ghani Kibbi

American University of Beirut

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Georges Nemer

American University of Beirut

View shared research outputs
Top Co-Authors

Avatar

Hussam Tamraz

American University of Beirut

View shared research outputs
Top Co-Authors

Avatar

Imad Uthman

American University of Beirut

View shared research outputs
Top Co-Authors

Avatar

J. A. Baki

American University of Beirut

View shared research outputs
Researchain Logo
Decentralizing Knowledge